33results about How to "Improve drug dissolution" patented technology

The invention discloses a levamlodipine besylate tablet. The tablet is prepared by mixing a medicine carrying pellet containing levamlodipine besylate and pharmaceutically-accepted accessories and then carrying out direct compression, wherein the medicine carrying pellet is prepared by using the following method comprising the following steps of: weighting levamlodipine besylate and polyethylene glycol according to the weight ratio of 1: (4-8), then, dissolving levamlodipine besylate and polyethylene glycol into an organic solvent; and spraying the formed solution on a lactose pellet in a fluidized bed, coating and drying to obtain the medicine carrying pellet. The levamlodipine besylate raw material is coated on the outer layer of the lactose pellet and medicine is uniformly distributed on the surface of the pellet, so that the specific surface area of the medicine is greatly increased; and the raw material can be rapidly released, and thus, the medicine dissolution rate and the bioavailability of the levamlodipine besylate tablet are increased.

The invention discloses a cefuroxime axetil capsule. The cefuroxime axetil capsule is prepared by filling the uniformly mixed cefuroxime axetil-containing medicine-carrying pills and talcum powder into a capsule shell; and the medicine-carrying pills are prepared according to the following steps of: weighing the cefuroxime axetil and a disintegrating agent to be dissolved or dispersed in acetone, spraying the formed solution or injectable suspension to lactose pills in a fluidized bed, and coating and drying to obtain the medicine-carrying pills. The cefuroxime axetil raw material is coated on the outer layers of the lactose pills and is uniformly distributed on the surfaces of the pills, the specific surface area of the medicine is greatly increased, the raw material can be quickly released, and thus, the dissolubility and bioavailability of the medicine are improved.

The invention discloses a glipizide tablet as well as a preparation method and an application thereof. The glipizide tablet comprises the following components in percentage by weight: 1-5% of glipizide with the particle diameter D50 being 50-100 micrometers, 1-10% of a solubilizer, 50-90% of a filler, 5-15% of a disintegrating agent, 0.1-5% of a lubricant, and a suitable amount of 2-15% adhesive, wherein glipizide is preferably glipizide with the particle diameter D50 being 50-75 micrometers. According to the invention, the active ingredient glipizide is micronized, so that the particle diameter of the bulk drug is reduced, meanwhile, the solubilizer is added to be matched with glipizide, so that the drug release rate is increased, further, the bioavailability is improved, and the quality of the product is improved.

The invention relates to a co-amorphous substance of puerarin nicotinamide, which can significantly improve dissolubility of an insoluble medicine, namely puerarin. The co-amorphous substance is in anamorphous state completely different from that of a puerarin crystal, and a melting point, an X-ray powder diffraction pattern, a DSC (differential scanning calorimetry) spectrogram and an infrared spectrum of the co-amorphous substance are different from those of the puerarin crystal. With the adoption of Cu-k alpha radiation, an X-ray powder diffraction spectrum expressed by 2 theta degree hasno sharp diffraction peak. A glass transition temperature of the substance is approximately 64.1 DEGC. A dissolving experiment result shows that the co-amorphous substance can increase an intrinsic dissolution rate of the puerarin by about 78 times and keep an oversaturation state higher than the dissolvability of the puerarin crystal for 24h.

The invention relates to medicine field, and particularly relates to an angiotensin II receptor antagonist valsartan dispersible tablet and a preparation method thereof. The prescription of the product comprises pharmaceutical adjuvants acceptable in pharmacy like valsartan bulk drug, a filler, a disintegrant, an adhesive, flow aid, a lubricant, and corrigent, and the dispersible tablet is prepared by a wet granulation method. The valsartan bulk drug needs to be micronized, and the diameter 90 is less than 75mu m, preferably, the diameter 90 is less than 10mu m. The size distribution of the valsartan bulk drug directly affects the dispersibility of the dispersible tablet. The valsartan has polymorphy, different crystal forms of valsartan have different size distribution, and the dispersibility of the valsartan dispersible tablet is more different. The size distribution of the valsartan bulk drug is controlled by virtue of the micronization technology, the diameter 90 is less than 75mu m, preferably, when the diameter 90 is less than 10mu m, the difference of size distribution of different crystal forms of valsartan bulk drug is eliminated, the dispersibility of the valsartan dispersible tablet is improved obviously, the drug dissolution rate of the valsartan dispersible tablet is improved, and the product quality is controllable and is improved remarkably.

The invention relates to Chinese yew micronized particles, a compound for health bath obtained by using micronized Chinese yew particle and a preparation method thereof. The preparation method of the micronized Chinese yew particles comprises the following steps of: mixing Chinese yew bark and/or root and micronized solid auxiliary agent so as to form a solid mixture; and crushing the solid mixture in a micronized manner so as to form mixture particles with particle sizes D(90) being smaller than or equal to 15 microns. According to the micronized method disclosed by the invention, the dissolution rate of effective constituents of Chinese yew bark and root is greatly improved, the utilization ratio of Chinese yew bark and root is greatly improved, the adhesion and blockage conditions in crushing are also reduced, the medicine loss is few, and the crushing efficiency of micronized medicine can be obviously improved.

The invention discloses a functional beverage capable of preventing and treating cold and cough. The functional beverage is prepared from such raw materials in parts by weight as 18-22 parts of honeysuckle flower, 7-12 parts of baical skullcap root, 12-20 parts of dandelion, 4-8 parts of liquorice root, 5-7 parts of apricot kernel, 8-12 parts of perilla fruit, 80-100 parts of honey, 120-200 parts of white granulated sugar and 9000-11000 parts of water. The invention also discloses a preparation method of the functional beverage. The invention provides a natural pure traditional Chinese medicine functional beverage according to a reasonable formula; after the Chinese herbs are fermented, the toxic and side effects of the Chinese herbs are eliminated; the medicinal ingredients are promoted to be dissolved out by virtue of fermentation and wall-breaking; in addition, various vitamins and amino acids as well as trace elements contained in the raw materials can be dissolved out by virtue of Bayer in combination with fermentation with saccharomycetes and acetobacter xylinum, and no any hormone and chemical component need to be added; as a result, the functional beverage can be drank to achieve the effect of preventing and treating the cold and cough, and also has the effects of health care, body building, and organism immunity enhancement; the popularization of the functional beverage benefits the country.

The present invention provides an allisartan isoproxil solid dispersion with high drug loading and stability. On that basis, it also provides an allisartan isoproxil pharmaceutical composition containing mentioned solid dispersion. Compared with available technologies, the mentioned allisartan isoproxil pharmaceutical composition is characterized by high stability, good dissolution performance, and improved patient compliance, etc.

The invention relates to a preparation method of a ranitidine hydrochloride capsule. The ranitidine hydrochloride capsule mainly contains the following raw materials by weight percentage: 55-99% of ranitidine hydrochloride; 0-30% of a filler; 0%-10% of a binder; 0-5% of a disintegrant; and 0. 01-5% of a lubricant. The employed optimized prescription and process preparation method effectively improve the process robustness, controllability and feasibility; the production process of the ranitidine hydrochloride capsule is simplified, the production operation cycle is shortened, and the production efficiency is improved.

The invention discloses a method for improving the dissolution rate of cefquinome sulfate and a method for detecting the dissolution rate of the cefquinome sulfate. The method comprises the followingsteps of 1) mixing soybean oil for injection and ethyl oleate according to a ratio of 5: 5, heating mixed liquid to 120 DEG C under the protection of N2, keeping the temperature for 2 hours, and cooling the liquid to the room temperature; 2) heating the mixed liquid to 60 DEG C, adding BHT, performing stirring and melting, adding hydrogenated castor oil and span 60 when the liquid is cooled to 40DEG C, performing stirring for 30 minutes, and performing cooling to the room temperature; and 3) adding a prescription amount of the cefquinome sulfate after all medicinal auxiliary materials are added, pouring the cefquinome sulfate into a colloid mill, and performing grinding for 5-20 minutes in a manner of alternating circulating grinding and non-circulating grinding. The particle size of thecefquinome sulfate is changed through the colloid mill, so that the drug dissolution rate of the cefquinome sulfate is increased; and through particle size detection and dissolution rate analysis, after grinding is conducted for 15-20 min, the cefquinome sulfate with the particle size of 10 microns or below accounts for 80%, and the dissolution rate is the best.

The invention discloses a solid cefpodoxime proxetil liposome preparation and a preparation method thereof. The liposome is prepared with an active ingredient cefpodoxime proxetil and particular combination of beta-sitosterol, stearamide, cholesterol and Tween 80. The stability, dissolution and bioavailability of drugs can be greatly improved, stable and lasting effects can be achieved, and the curative effect is significant. The preparation product quality is improved, and toxic side effects are reduced.

The invention discloses a taxus chinensis medicated bath formula and a preparation method thereof. The formula comprises folium artemisiae argyi, safflower carthamus, ligusticum chuanxiong hort, monkshood, radix cyathulae, cinnamon, radix clematidis, asarum and taxus chinensis essential oil powder. The preparation method comprises the preparation method of the taxus chinensis essential oil powderand the preparation method of taxus chinensis medicated bath powder, wherein the preparation method of the taxus chinensis essential oil powder comprises pretreatment, essential oil extraction and adsorption. The taxus chinensis medicated bath powder prepared by the preparation method is safe and non-toxic, enables the dissolution rate of beneficial components to be high by utilizing the volatility of the essential oil, and can promote metabolism, promote blood circulation and improve sleep. The principle is as follows: diffusion of the medicine components in the essential oil and warm stimulation can be conducted to a central nervous system through a touch receptor and a skin receptor, so that excitement and inhibition of the central pivot are ordered. The taxus chinensis medicated bath formula has the effects of activating main and collateral channels, dispelling cold and removing dampness as well as promoting blood circulation to remove blood stasis, and has a good effect of preventing and regulating rheumatism, rheumatoid as well as pain in the neck shoulder low-back.

The invention provides a Meisuoshuli suppository, and a preparation method and a use thereof. The Meisuoshuli suppository comprises Meisuoshuli and pharmaceutically acceptable auxiliary materials. The Meisuoshuli suppository has high dissolution rate and no irritation, has very good fever relieving, pain easing and inflammation preventing effects, has the advantages of large drug load, small administration frequency, simple use, low price, economy and practicality, and is very convenient for old people, children or unable oral administration patients to administrate.

The invention discloses a method for improving the dissolution rate of triclabendazole particles and a dissolution rate detection method of the triclabendazole particles. The method comprises the following steps: firstly, mixing water, 95% ethanol, sorbitan monooleate and polyvinylpyrrolidone K30 according to a ratio of 3: 6: 0.4: 0.6, stirring and dissolving to obtain a clear and uniform composite solution for later use; then mixing triclabendazole, starch and glucose in a high-speed mixing pot according to a ratio of 1: 1: 8 for 5 minutes, slowly adding the mixture into the composite solution in the step S1 according to a ratio of 5% by adopting a method of stirring while adding, and then mixing for 5-10 minutes to prepare a soft material; and finally, feeding the soft material to a granulator, granulating with a 18-mesh screen, collecting, and drying in a drying oven. Compared with the prior art, the method for preparing the triclabendazole granules by using the composite solution has the advantages that the drug dissolution rate of the triclabendazole granules is improved, and the triclabendazole granules prepared from water, 95% ethanol, sorbitan monooleate and polyvinylpyrrolidone K30 according to the ratio of 3: 6: 0.4: 0.6 have the best dissolution rate.